Stay updated on Grapiprant and Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page
- Check5 days agoChange DetectedA site-wide notice about a lapse in government funding was added, informing users that information may not be up to date and directing them to opm.gov for updates. The page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check12 days agoChange DetectedThis update adds a glossary option and standardizes capitalization of metadata labels (e.g., 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data') along with a new Revision: v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check19 days agoChange DetectedRevision update from v3.3.3 to v3.3.4; no visible changes to study content or page functionality detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page's Locations section was updated to include entries for California, Michigan, Pennsylvania, and Virginia, and the revision tag updated to v3.3.3; the HHS Vulnerability Disclosure link was removed.SummaryDifference0.6%

- Check69 days agoChange DetectedThe page shows a revision update to v3.3.2, replacing the previous v3.3.1. No substantive study details, eligibility criteria, endpoints, or enrollment changes are observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check76 days agoChange DetectedRevision history updated from v3.2.0 to v3.3.1; no changes to study details or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Grapiprant and Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.